The H-Y and minor histocompatibility antigens have been identified as T cell targets in patients with hematological malignancies after allogeneic hematopoietic stem cell transplantation and have thus been confirmed to be immunogenic in vivo (35, 36). The gene discussed is KDM5D; the disease is hematologic disorder.